A QbD approach to shorten tablet development time. Cazes, R. Pharmaceutical technology, Supplement to March 2018:16–20, March, 2018.
abstract   bibtex   
Reducing “time to market” is the ultimate goal for every pharmaceutical lab. Being the first on the market brings a competitive advantage for prescription, over-the-counter, or generic-drug manufacturers. Applying quality-by-design (QbD) principles at the formulation phase can prevent tablet defects at an early stage and thereby drastically reduce time during the complex and troublesome phase of “scaleup.” Waiting until late in development in the “production-size phase” may force scientists to solve formulation issues at the pilot level or—even worse—in actual production. A QbD approach, however, secures the scale-up to production with maximum safety right from the beginning.
@article{cazes_qbd_2018,
	title = {A {QbD} approach to shorten tablet development time},
	volume = {Supplement to March 2018},
	abstract = {Reducing “time to market” is the ultimate goal for every  pharmaceutical lab. Being the first on the market brings a  competitive advantage for
prescription, over-the-counter, or generic-drug manufacturers. Applying quality-by-design
(QbD) principles at the formulation phase can
prevent tablet defects at an early stage and
thereby drastically reduce time during the
complex and troublesome phase of “scaleup.”
Waiting until late in development in the “production-size phase” may force scientists to
solve formulation issues at the pilot level or—even
worse—in actual production. A QbD approach,
however, secures the scale-up to production
with maximum safety right from the beginning.},
	journal = {Pharmaceutical technology},
	author = {Cazes, Régis},
	month = mar,
	year = {2018},
	keywords = {QbD, Stylone},
	pages = {16--20}
}

Downloads: 0